Researchers at the Weizmann Institute of Science have developed a novel minimally invasive blood test that detects early signs of leukemia risk by analyzing genetic alterations in hematopoietic stem cells. This test, published in Nature Medicine, may replace the invasive bone marrow biopsies traditionally used. The study underscores that mutations in blood stem cells of aging adults correlate not only with blood malignancies but also with other systemic diseases, suggesting a broader diagnostic potential for hematologic and metabolic conditions.